One plant. Two catalogs. A partnership that starts with a real product list.

Most partners sourcing oncology injectables assemble a supply chain from separate API and finished-dose vendors, each with its own quality system, timeline, and audit calendar. Naprod's finished-dose formulation (FDF) manufacturing and MacChem's active pharmaceutical ingredient (API) production are a group vertical integration — API supply and FDF manufacturing sit inside the same corporate group, coordinated rather than brokered.

The practical effect for a partner: one regulatory point of contact across API and finished dose, one coordinated group quality function instead of separately brokered vendors, and — for Naprod's finished-dose portfolio — a single accredited manufacturing site (MIDC Tarapur, Boisar, Maharashtra) whose accreditation register (EU-GMP, WHO-GMP, ANVISA, INVIMA, UAE MOHAP, and NHRA Bahrain among them) is verifiable against the issuing authorities.

Naprod's contract development and manufacturing (CDMO) offer draws on the same six production lines behind our own portfolio: oncology lyophilized and liquid injectables, tablets, capsules, and general (non-oncology) lyophilized and liquid injectables. A partner bringing a molecule to Tarapur is scheduled against real, already-qualified capacity — not a greenfield build.

What's in scope depends on dosage form, sterility requirements, and current line utilization at the time of enquiry; Naprod's business-development and regulatory teams confirm fit and lead time directly rather than publishing a standing capacity commitment here.

Pending approval CDMO scope, minimum order quantities, and line availability are confirmed per-enquiry — not published as fixed terms on this page.

Naprod's R&D function currently has 24 products in official development, spanning formulation and analytical work behind future filings across SRA, ROW, and domestic markets. Out-licensing conversations — dossier transfer, technology transfer, or co-development on a pipeline molecule — start from that list, not from a blank slate.

Detail on the pipeline itself, including therapeutic area and dossier status per product, lives on the Research & Development page (/capabilities/research-development).

Naprod's distribution partnerships are strongest where a regulatory approval already exists at the plant level. Brazil (ANVISA) and Colombia (INVIMA) in Latin America, the UAE (Ministry of Health and Prevention) and Bahrain (NHRA) in the Middle East, and the wider WHO-GMP footprint across Africa, Southeast Asia, CIS, and South Asia each anchor a different distribution conversation. Country-level distributor agreements and registration counts beyond the accreditations named above are confirmed case by case — the current published state of that register is on the Global Presence page (/global-presence).

Pending approval Distributor relationships and country-level registration counts beyond the named accreditations are pending company confirmation.